{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:42:35Z","timestamp":1794440555202,"version":"4.9.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that can present with drug-induced liver injury (DILI), often mimicking acute liver failure and delaying diagnosis. Therapeutic options are limited in patients with severe hepatic dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe the clinical features, treatment, and outcomes of three adult patients presenting with DILI-mimicking HLH and evaluate the effectiveness of low-dose ruxolitinib combined with corticosteroids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three patients with DILI-like hepatic injury and secondary HLH were retrospectively analyzed. All patients exhibited severe hyperbilirubinemia and cytopenias refractory to conventional supportive therapy. Low-dose ruxolitinib plus corticosteroids were administered. Laboratory, imaging, genetic, and histopathological data were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients responded rapidly to the combination therapy, with progressive normalization of bilirubin and inflammatory markers. Transient declines in blood counts occurred but resolved without intervention. Genetic testing revealed heterozygous variants in immune-regulatory genes (NLRP3, DOCK8, MYO5A, PLCG2) classified as variants of uncertain significance, suggesting a potential predisposing role. No significant adverse events related to ruxolitinib were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HLH can initially present as severe DILI, posing diagnostic challenges. Short-course, low-dose ruxolitinib combined with corticosteroids is a safe and effective treatment in patients with hepatic-predominant HLH. Early recognition and timely immunomodulatory therapy may improve outcomes in this life-threatening but treatable condition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1856139","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:58:00Z","timestamp":1779944280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luocheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"West China Medical School, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xushu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031100","article-title":"Hemophagocytic lymphohistiocytosis in adults","volume":"147","author":"Hsu","year":"2026","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882589","article-title":"Epstein-Barr virus-positive lymphoma-associated hemophagocytic syndrome: A retrospective, single-center study of 51 patients","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B4","article-title":"Diagnosis and treatment of secondary hemophagocytic lymphohistiocytosis in adults","volume":"23","author":"Shakoory","year":"2025","journal-title":"Clin Adv Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","article-title":"Hemophagocytic lymphohistiocytosis: Current treatment advances, emerging targeted therapy and underlying mechanisms","volume":"17","author":"Wu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: A literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1108345","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: A narrative review","volume":"10","author":"Manieri","year":"2023","journal-title":"Front Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.1801","article-title":"A fatal case of drug reaction with esoinophilia and systemic symptoms (DRESS): Hemophagocytic lymphohistiocytosis (HLH) overlap syndrome","volume":"166","author":"Reet","year":"2024","journal-title":"CHEST"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15196","article-title":"Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: A review","author":"Yang","year":"2020","journal-title":"Int J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2204547","article-title":"Drug reaction with eosinophilia and systemic symptoms","volume":"391","author":"Kroshinsky","year":"2024","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.100848","article-title":"Navigating a dual hyperinflammatory state: Overlap of drug reaction with eosinophilia and systemic symptoms (DRESS) and secondary hemophagocytic lymphohistiocytosis (HLH) in a child","volume":"18","author":"Gupta","year":"2026","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-016-0638-7","article-title":"Drug-induced liver injury with autoimmune features complicated with hemophagocytic syndrome","volume":"9","author":"Hayashi","year":"2016","journal-title":"Clin J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102455","article-title":"DRESS syndrome associated with a hemophagocytic lympho-histiocytosis: A rare presentation of DILI induced by a nutritional supplement","volume":"48","author":"Lemmens","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4253\/wjge.v4.i8.376","article-title":"Drug associated vanishing bile duct syndrome combined with hemophagocytic lymphohistiocytosis","volume":"4","author":"Li","year":"2012","journal-title":"World J Gastrointest Endosc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13667","article-title":"Clinical features, treatment outcomes and prognostic factors of allopurinol-induced DRESS in 52 patients","volume":"47","author":"Liu","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1023522","article-title":"Case report: Drug reaction with eosinophilia and systemic symptoms (DRESS)-induced hemophagocytic disorder","volume":"13","author":"Pope","year":"2022","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000045675","article-title":"Piperacillin-tazobactam-induced hemophagocytic lymphohistiocytosis in a patient with community-acquired pneumonia: A case report and literature review on diagnostic challenges of elevated procalcitonin","volume":"104","author":"Xia","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/jaa.s505666","article-title":"Carbamazepine-induced DRESS complicated by HLH and VBDS: A case report","volume":"18","author":"Zhang","year":"2025","journal-title":"J Asthma Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13256-019-2295-1","article-title":"Lamotrigine-induced hemophagocytic lymphohistiocytosis with Takotsubo cardiomyopathy: A case report","volume":"13","author":"Zhou","year":"2019","journal-title":"J Med Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115921","article-title":"Pathogenesis of hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: A case report and review of the literature","volume":"25","author":"Gioia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s42358-024-00370-2","article-title":"Hemophagocytic lymphohistiocytosis and macrophage activation syndrome: Two rare sides of the same devastating coin","volume":"64","author":"Sztajnbok","year":"2024","journal-title":"Adv Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: Mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021046","article-title":"Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis","volume":"143","author":"Keenan","year":"2024","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000022","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1856139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:58:26Z","timestamp":1779944306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1856139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1856139"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1856139","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"article-number":"1856139"}}